Home » Posts tagged with » China
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]

Gsport creates cohesive bandages for human and animal patients

Gsport, a Chinese sports medicine company claims to have created high-quality cohesive bandages for human and animal patients. The company, which manufactures therapeutic products in its Zhejiang facility, has expanded its business into the US. Its products range from cold bags, athletic tape, and kinesiology tape for athletic care. All the athletic care products are […]

Continue reading …
Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Continue reading …
Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818

Chinese pharma company Kangpu Biopharmaceuticals said that it has wrapped up the first-in-human phase 1 clinical trial of CRL4-CRBN modulator KPG-818 in the US. KPG-818 is being developed for the treatment of systemic lupus erythematosus (SLE) or hematological malignancies. The single ascending dose (SAD) randomized, double-blind, placebo-controlled study assessed the safety, tolerability, and pharmacokinetics of […]

Continue reading …
CMAB Biopharma, BJ Bioscience join forces for bi-functional antibody BJ-005

CMAB Biopharma (Suzhou), a pure-play biologics CDMO, and BJ Bioscience have signed an agreement for the development and manufacturing of a bi-functional antibody called BJ-005 as the first initiative in an exclusive collaboration. As per the terms of the agreement, CMAB will offer a complete range of CMC research and manufacturing services that address the […]

Continue reading …
Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506

Chinese biotech company Bio-Thera Solutions has started dosing in a phase 1 clinical trial to study the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Janssen Biotech’s Simponi (golimumab). The early-stage clinical study is a randomized two-arm, parallel-group trial that will have nearly 182 healthy volunteers. Each of the patients will be subjected to […]

Continue reading …
NKF to invest $95m in US generic injectables company Meitheal

Pharma acquisition news : Hong Kong King-Friend Industrial Company, a subsidiary of Chinese manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF), has agreed to increase its stake in US generic injectables company Meitheal Pharmaceuticals for $95 million. Following the completion of the transaction, which is likely to be in Q4 2019, NKF will have a majority stake […]

Continue reading …
Boston Scientific to be distributor of Endologix products in China

US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China. The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also […]

Continue reading …
Gilead Sciences announces Biktarvy China approval for HIV-1

Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]

Continue reading …
Page 1 of 212